Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Market Access

Viehbacher says two Biogen drugs likely launching into headwinds

The biotech’s CEO discusses the promise and the challenges ahead for Leqembi and zuranolone

March 6, 2023 11:57 PM UTC


Biogen has a lot riding on two upcoming product launches, but as it looks forward to FDA decisions on the therapies this summer, CEO Christopher Viehbacher acknowledges ramp up “is not going to be so easy” for either therapy.

Biogen Inc. (NASDAQ:BIIB) is hoping to offset the sagging revenues of its multiple sclerosis franchise with Alzheimer’s disease therapy Leqembi lecanemab-irmb and depression treatment zuranolone. Both products are under priority review. Leqembi has a July 6 PDUFA date on an application to convert its accelerated approval into a full approval, and zuranolone has an Aug. 5 PDUFA for both major depressive disorder and postpartum depression. Biogen expects FDA to hold an advisory committee meeting on Leqembi, though a date has yet to be announced...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Target Profiles

Beta amyloid